Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring.

ABSTRACT:

Importance

Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

Objective

To explore whether differential censoring-that is, censoring imbalance between the study groups-is a possible explanation for these inconsistent findings.

Design, setting, and participants

This comparative effectiveness study involved a censoring analysis

SUBMITTER: Meirson T 

PROVIDER: S-EPMC11755191 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature